Market Closed -
Nyse
01:30:02 16/05/2024 am IST
5-day change
1st Jan Change
8.66
USD
-4.20%
-10.72%
-16.33%
This article is reserved for members
Not a member ?
Free registration
Leerink Partners Upgrades Enhabit to Market Perform From Underperform, Price Target is $8.50
14/05
MT
UBS Trims Price Target on Enhabit to $9 From $10, Keeps Neutral Rating
10/05
MT
Transcript : Enhabit, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05
AREX Capital Expresses Disappointment in Enhabit?s Strategic Review Conclusion
09/05
CI
AREX Capital to mount board challenge against Enhabit, sources say
09/05
RE
Jefferies Downgrades Enhabit to Hold From Buy, Price Target at $8.75
09/05
MT
(EHAB) ENHABIT Sees Fiscal Year 2024 Revenue Range $1.08B - $1.1B
09/05
MT
(EHAB) ENHABIT Expects Fiscal Year 2024 EPS Range $0.12 - $0.43
09/05
MT
Earnings Flash (EHAB) ENHABIT Reports Q1 EPS $0.07, vs. Street Est of $0.05
09/05
MT
Enhabit, Inc. Reaffirms Earnings Guidance for the Full-Year 2024
09/05
CI
Enhabit, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
09/05
CI
Enhabit Concludes Review of Strategic Alternatives
08/05
CI
UBS Adjusts Enhabit Price Target to $10 From $9.50, Maintains Neutral Rating
08/03
MT
North American Morning Briefing : Stock Futures -2-
08/03
DJ
UBS Upgrades Enhabit to Neutral From Sell, $9.50 Price Target
07/03
MT
Transcript : Enhabit, Inc., 2023 Earnings Call, Mar 07, 2024
07/03
North American Morning Briefing : Powell Still in -2-
07/03
DJ
Enhabit, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
07/03
CI
Earnings Flash (EHAB) ENHABIT Reports Q4 EPS $0.06, vs. Street Est of $0.03
07/03
MT
Jefferies Adjusts Price Target on Enhabit to $14 From $15, Maintains Buy Rating
06/03
MT
North American Morning Briefing : Stock Futures -2-
06/03
DJ
TD Cowen Starts Enhabit With Market Perform Rating
12/12
MT
Transcript : Enhabit, Inc., Q3 2023 Earnings Call, Nov 08, 2023
08/11
Enhabit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
08/11
CI
Enhabit, Inc. Enters Second Amendment to the Credit Agreement
08/11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Enhabit, Inc. is a provider of home health and hospice services. The Companyâs segments include Home Health and Hospice. The Home Health segment provides a range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational and speech therapy, medical social work, and home health aide services. Its home health business benefits from a diversity of referral sources, with patients referred from acute care hospitals, inpatient rehabilitation facilities, surgery centers, assisted living facilities, and skilled nursing facilities, as well as community physicians. The Hospice segment provides hospice services for terminally ill patients and their families. Its Medicare-certified hospice operations provide hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and family member bereavement counseling. It operates over 110 hospice agencies and 255 home health agencies.
More about the company
Last Close Price
8.66
USD
Average target price
9.75
USD
Spread / Average Target
+12.59%
Consensus
1st Jan change
Capi.
-16.33% 434M 0.00% 1.99B +19.41% 1.79B +64.22% 687M -39.89% 341M -19.03% 164M -15.75% 137M +1.92% 67.85M
Home Healthcare Services
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**